insulin analog

(redirected from Insulin analogue)

insulin analog

A synthetic insulin in which small changes in the amino acid structure of the polypeptide result in changes in the onset, peak effect, or duration of the molecule's physiological effects. Insulin aspart, glargine, and lispro are all insulin analogues.
See also: analogue
References in periodicals archive ?
Tenders are invited for Rapid Acting Insulin Analogue Like Insulin Aspart Or Insulin Glulisine Or Insulin Lispro Cartridge 100 Iu Per Ml, 3 Ml Cartridges With Complementary Pen In The Ratio Of 5 Cartridge To One Pen
Inj Human Insulin analogue 30/70 40 IU/mlm, Syringe Disposable Insulin 40 IU, Peritoneal Dialysis Solution, Peritoneal Dialysis Solution, And CAPD Mini Caps (Baxter).
10 Fast-Acting Insulin Analogue Submarket by Drug: Revenues, 2011-2012 Table 6.
The data discussed demonstrated the clinical benefits of Levemir(R) and illustrated how this new basal insulin analogue can help realise the maximum potential of insulin therapy.
Tenders are invited for Human Insulin Analogue Inj.
Novolog (insulin aspart, [rDNA origin] injection), a rapid-acting insulin analogue, is now available in the FlexPen prefilled syringe for treating diabetes.
Lilly's two basal insulin analogue candidates are expected to enter Phase III clinical testing in 2011.
3) Gammeltoft S, Hansen BF, Dideriksen L, Lindholm A, Schaffer L, Trub T, Dayan A, Kurtzhals P (1999): Insulin aspart, a novel rapid-acting human insulin analogue.
This is the first study that demonstrated that patients with Type 1 diabetes using Technosphere Insulin can achieve comparable levels of control in HbA1c as patients treated with an injected rapid-acting insulin analogue," said Dr.
This novel basal insulin analogue with no pronounced peak, which provides 24-hour basal glucose control while being administered just once per day, generated sales of euro 487 million in 2003.
NovoMix(R) 30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]), a dual-action insulin analogue, is more effective in helping people with diabetes who are adding insulin therapy to sensitisers achieve control of their blood glucose levels compared to insulin glargine, according to data from the INITIATE (INITiation of Insulin to reach A1c TargEt) study presented today at the 64th annual meeting of the American Diabetes Association (ADA) in Orlando, Florida.
Apidra is a recombinant DNA human insulin analogue that has a more rapid onset and a shorter duration of action than regular human insulin after subcutaneous administration.